Associated Papers
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers.
Gutta R et al.
Clinical Lung Cancer, 2025
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations.
Cheunkarndee T et al.
Jto Clinical and Research Reports, 2024
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib.
Liang SK et al.
Erj Open Research, 2024
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study.
Ikeda S et al.
Molecular Oncology, 2024
Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M et al.
Lung Cancer (amsterdam, Netherlands), 2020
Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.
Cho WCS et al.
Oncotarget, 2018
Select a paper to view details